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The formation of a novel trichain (TC) lipid was discovered when a cationic lipid possessing a terminal
hydroxyl group and the helper lipid dioleoyl L-α-phosphatidylethanolamine (DOPE) were formulated as
vesicles and stored. Importantly, the transfection eﬃcacies of lipopolyplexes comprised of the TC lipid, a
targeting peptide and DNA (LPDs) were found to be higher than when the corresponding dichain (DC)
lipid was used. To explore this interesting discovery and determine if this concept can be more generally
applied to improve gene delivery eﬃciencies, the design and synthesis of a series of novel TC cationic
lipids and the corresponding DC lipids was undertaken. Transfection eﬃcacies of the LPDs were found to
be higher when using the TC lipids compared to the DC analogues, so experiments were carried out to
investigate the reasons for this enhancement. Sizing experiments and transmission electron microscopy
indicated that there were no major diﬀerences in the size and shape of the LPDs prepared using the TC
and DC lipids, while circular dichroism spectroscopy showed that the presence of the third acyl chain did
not inﬂuence the conformation of the DNA within the LPD. In contrast, small angle neutron scattering
studies showed a considerable re-arrangement of lipid conformation upon formulation as LPDs, particu-
larly of the TC lipids, while gel electrophoresis studies revealed that the use of a TC lipid in the LPD formu-
lation resulted in enhanced DNA protection properties. Thus, the major enhancement in transfection per-
formance of these novel TC lipids can be attributed to their ability to protect and subsequently release
DNA. Importantly, the TC lipids described here highlight a valuable structural template for the generation
of gene delivery vectors, based on the use of lipids with three hydrophobic chains.
Introduction
Non-viral vectors continue to have significant potential to
facilitate DNA or RNA delivery into target cells.1 Synthetic cat-
ionic lipids (cytofectins) have been used in many lipid-DNA
formulations, and since the report of the cytofectin DOTMA2
which is often used with the neutral lipid dioleoyl
L-α-phosphatidylethanolamine (DOPE) (Fig. 1), a range of
related lipids have been described.1e,3 The aim in developing
new cytofectins has been to optimise the delivery properties of
the resulting vector for a wide variety of cell types, and for
in vivo applications.2,3 Cytofectins are typically used in lipoplex
(lipid-DNA; LD) binary formulations or lipopolyplex (lipid-poly-
cation/peptide-DNA; LPD) ternary formulations where the poly-
cation/peptide has DNA-binding functionality and peptides
can also have cell-targeting capability.1e,4–6
Cationic lipids are made up of a positively charged head
group with a linker to a hydrophobic component. Since
DOTMA was first described, analogues with ether or ester link-
ages to the glycerol skeleton, alternative alkyl chain groups
and functionalized head groups have been reported. Examples
include the diester DOTAP,7 diester DORI and corresponding
diether DORIE, and DMRIE (Fig. 1).3,8 Such hydroxyalkyl cyto-
fectins were reported to be more active than DOTMA.8 It was
postulated that they were particularly eﬀective, either because
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the hydroxyl group was able to increase the liposome inter-
action with DNA or cellular membranes, or because it was able
to stabilize the cationic lipid : DOPE bilayer structure, through
charge neutralization and/or hydrogen bonding.8 Others have
also incorporated hydroxyalkyl chains onto quaternary amine
species with varying results.9,10
Alterations to the alkyl chain, including factors such as
chain saturation, double bond geometry, and chain length
have been shown to be important in lipoplex and lipopolyplex
formulations.11–17 In addition, other head groups such as
aminopropyl groups, and short polyethylene glycol (PEG)
shielded glycerol-based lipids with non-cleavable and cleavable
functionalities have been reported.14,16–20 Studies established
that shielding nanoparticles with long PEG-lipid conjugates,
while enhancing circulation times and reducing vesicle aggre-
gation, resulted in lower transfections eﬃciencies.16 However,
the use of short n-ethylene glycol (n-EG) moieties attached to
lipid headgroups still gave improved LPD particle stabilities
but enabled nanoparticle targeting and good in vitro and
in vivo transfection eﬃciencies.16–20
Addition of the neutral co-lipid DOPE is often found to
enhance transfection levels, and is attributed to improved
endosomal membrane fusion, due to the presence of DOPE
changing the bilayer Lα phase into the inverted hexagonal HII
phase, promoting endosomal escape.3,8,9 An enhanced trans-
fection however is not always observed, for example in formu-
lations of DOPE with βAE-DMRIE.21
Interestingly, some groups have reported that on storage,
an acyl chain transfer reaction can occur from an acyl chain on
the DOPE lipid to the terminal primary amine of the co-formu-
lated lipid.22,23 It was noted in experiments with the chole-
sterol lipid GL-series, such as GL-67, and DOPE (Scheme 1) co-
formulated in aqueous media, that transfection levels dimin-
ished by 10–20 fold.22 When the GL-lipids were formulated
with other co-lipids this was not the case and transfections
levels were enhanced. HPLC analysis of mixtures of GL-67 and
DOPE revealed the formation of lyso-PE (1 and 2) and ami-
dated GL-67 such as 3. Analysis of the reaction revealed a 6%
conversion after 5 h in hydrated mixtures, but very low levels
when stored as dried lipid films.22 Lyso-PE (1 and 2) and 3
were tested in transfection experiments which confirmed they
were ineﬀective transfection reagents, and when lyso-PE was
added to GL-67/DOPE formulations, lower levels of transfec-
tion were also observed.22 The acyl chain transfer eﬀect was
also highlighted with an analogue of GL-67.22 A similar acyl
chain transfer reaction has been noted with diester lipids pos-
sessing a primary amine head group, where some fluorinated
analogues were less prone to acyl transfer.9 It is unclear
whether the acyl transfer reaction from DOPE to cationic lipids
possessing a terminal primary amine group is a general
phenomenon, but reduced levels of transfection were observed
in the compounds studied, presumably due to reduced
capacity of the lipids to be protonated and induce endosomal
breakdown as well as changes to the molecular architecture of
the nanoparticles formed.
Here we report that in the course of our studies on gene
delivery using cytofectins possessing hydroxyl terminated
short n-EG head groups, it was noted that when lipid DODEG4
was co-formulated as vesicles with DOPE and stored for
periods of up to several months before peptide was added to
prepare an LPD, a trichain (TC) lipid TC-DODEG4 was formed
that gave improved levels of LPD transfection (Scheme 2A).
This transacylation of an acyl chain from DOPE to the terminal
hydroxyl group occurred in an analogous fashion to that
observed with GL-67 (Scheme 1).22 Therefore, several hydroxyl
terminated short n-EG lipids were prepared and the corres-
ponding TC-lipids, then LPD transfection experiments and
biophysical characterisations performed to understand this
Scheme 1 Acyl transfer from DOPE to give lyso-PE (1 and 2) and ami-
dation products of GL-67 such as 3.23
Fig. 1 Structures of a selection of cationic lipids: DOTMA, DOTAP,
DORI, DORIE, DMRIE, βAE-DMRIE and the helper lipid DOPE.
Paper Organic & Biomolecular Chemistry
946 | Org. Biomol. Chem., 2019, 17, 945–957 This journal is © The Royal Society of Chemistry 2019
change in eﬃcacy. The transacylation reaction is of importance
because there are many hydroxyl, n-EG and PEG terminated
lipids in use that when formulated with DOPE may be aﬀected
by this process. In addition, this may lead to the identification
of new improved compounds for delivery applications.
Results and discussion
Synthesis and lipid transacylation
We have previously reported the use of the lipid, DODEG4, a
glycerol-based diether lipid possessing a short n-EG headgroup
for applications in LPD targeted delivery.17 The lipid has been
used with the co-lipid DOPE, to provide a short n-EG layer to
shield nanoparticles for enhanced stabilities, while still
enabling peptide targeting to be achieved.17,20 Interestingly
when liposomal formulations of DODEG4 : DOPE were stored
at 4 °C for several months, then used in the preparation of
LPDs containing peptide A (Scheme 2B) and transfections
examined in a range of cell types including HAE and NIH3T3
cells, improved transfection eﬃciencies were noted when com-
pared to LPDs prepared from freshly made vesicles. MS-ana-
lysis revealed that a transacylated trichain lipid, TC-DODEG4,
had formed (Scheme 2A). Consequently, the chemical stability
of the lipid, DODEG4 (in the presence or absence of DOPE)
was investigated, over a period of one month, using TLC ana-
lysis and LC-MS. As expected, when the lipids were stored in
an organic solvent (CHCl3) no changes in lipid structure were
observed by LC-MS. When DODEG4 was formulated, in the
absence of DOPE, as liposomes dispersed in water at pH 5 and
pH 7.5, no new compounds were again formed. For liposomal
formulations made using a 1 : 1 molar ratio of
DODEG4 : DOPE dispersed in water at pH 7 however, the slow
formation of TC-DODEG4 (m/z 1061) together with lyso-PE
(1 and/or 2) (m/z 479) was observed (Fig. S1 ESI†) as a conse-
quence of transfer of an oleoyl chain from DOPE. When the
liposomes containing DODEG4 : DOPE (1 : 1) were dispersed in
water at pH 5, the transacylation to give TC-DODEG4 and lyso-
PE (1 and 2) was more pronounced (Fig. 2).
To probe the behaviour of these dichain (DC) and trichain
(TC) lipids in detail, several structurally related terminal n-EG
DC and the corresponding TC lipids were prepared for investi-
gation and application in LPD gene transfections (Scheme 2
and Table 1, referred to as Group 1 lipids). DODEG4
(Scheme 2A) was synthesized as previously reported, from the
diether 4 and 4-EG bromide 5. A diester analogue DOesDEG4
(structure in Scheme 2B) was similarly prepared via the quater-
nisation of 6 8 with 5. The corresponding TC lipids
Scheme 2 (A) Formation of TC-DODEG4 from DODEG4 and DOPE. (B) Structures of lipids DOesDEG4 and Me-DOesDEG3, Peptide A, sc and K16.
(C) Synthesis of TC-lipids. Reagents and conditions: (i) oleic acid, DMAP, DIC, CH2Cl2, 54%; (ii) for TC-DODEG4 acetone, 90 °C, 36%; for
TC-DOesDEG4 acetone, 80 °C, 11%; (iii) 5, DMAP, py, Ac2O, for 10 36%; 5, H15C7COCl, DMAP, Et3N, for 11 52%; 5, H23C11COCl, DMAP, Et3N, for 12
54%; (iv) acetone, 90 °C, AC-DODEG4 30%, AC-DOesDEG4 55%, OC-DODEG4 60%, DO-DODEG4 19%, DO-DOesDEG4 52%.
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TC-DODEG4 and TC-DOesDEG4 were synthesized by the qua-
ternisation of 4 and 6 with the 4-EG oleoyl ester 7, prepared
from oleic acid and bromide 5 (Scheme 2C).
Compounds TC-DODEG4 and TC-DOesDEG4 were formed
in 36% and 11% yield respectively, reflecting the general
diﬃculties in purifying the lipids. In addition, the di- and tri-
esters DOesDEG4 and TC-DOesDEG4 showed a tendency to
hydrolyse when undergoing purification on silica. A methoxy-
capped analogue of DOesDEG4, Me-DOesDEG3 (structure in
Scheme 2B), was also synthesized from amine 6 and 1-(2-bro-
moethoxy)-2-(2-methoxyethoxy)ethane24 as this is a lipid that
cannot undergo transacylation with DOPE (Scheme 2).
A further set of lipids were prepared based upon a pre-
viously reported short n-EG terminated lipid DOSEG3, eﬀective
in targeted LPD transfections (Table 1; Group 1 lipids).19 This
lipid possesses an endosomal esterase cleavable functionality
to release the n-EG group to enhance endosomal breakdown,
and was prepared as previously described via the quaternisa-
tion of 4 and the n-EG ester-bromide 8.19 In addition to
DOSEG3, the novel dichain diester analogue DOesSEG3 was
prepared, which may have greater biodegradability, and the
corresponding methoxy capped analogue Me-DOesSEG3 (struc-
tures in Scheme 3A). They were synthesized by the reaction of
bromides 8 19 and 9 19 with the tertiary amine 6, in 78% yield
(4, 6, 8, 9 are in Scheme 3B).
Two trichain lipids were also synthesized based on DOSEG3
and DOesSEG3, TC-DOSEG3 and TC-DOesSEG3. The n-EG
bromide 8 was coupled to oleic acid in 75% yield, and the
product reacted with the corresponding tertiary amines 4 and
6 to give TC-DOSEG3 and TC-DOesSEG3 (Scheme 3C). Again,
purification of the final TC-lipids was not straightforward, and
compounds were purified at least twice by silica column
chromatography.
Fig. 2 Formation of TC-DODEG4 and lyso-PE (1 and 2) from DODEG4
and DOPE, at pH 5 monitored by LC-MS.
Table 1 Summary of the dichain and trichain lipid prepared (Group 1
lipids) and dichain lipids capped with diﬀerent ester chain lengths
(Group 2 lipids)
DOTMA-based
ether series
DOTAP-based
ester series
Group 1 lipids
DODEG4 DOesDEG4
TC-DODEG4 TC-DOesDEG4
Me-DOesDEG3
DOSEG3 DOesSEG3
TC-DOSEG3 TC-DOesSEG3
Me-DOesSEG3
Group 2 lipids
AC-DODEG4 AC-DOesDEG4
OC-DODEG4
DO-DODEG4 DO-DOesDEG4
TC-DODEG4 TC-DOesDEG4
, Ether lipid; , ester lipid; , C18-chain; , acetyl group; , octa-
noyl group; , dodecanoyl group; , 3-PEG , Me capped
3-PEG; 4-PEG; , directly linked; , longer cleavable linker.
Scheme 3 (A) Structures of lipids DOSEG3, DOesSEG3, Me-DOesSEG3.
(B) Structures of substrates 4, 6, 8, 9. (C) Synthesis of TC-DOSEG3 and
TC-DOesSEG3. Reagents and conditions: (i) oleic acid, DMAP, DIC,
CH2Cl2, 75%; (ii) for TC-DOSEG3, 4, acetone, 90 °C, 11%; TC-DOesSEG3,
6, acetone, 90 °C, 45%.
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In addition to this first group of cytofectins (Group 1 lipids)
comprised of traditional dialkenyl chains and the new TC
series, a second group of cytofectins (Group 2 lipids) based on
DODEG4, but capped with acyl chains of diﬀerent lengths,
were prepared to probe the eﬀect of the length of the third
chain. This type of the TC lipid was denoted by the length of
the third acyl chain, namely either an acetyl (AC–), octanoyl
(OC–) or a dodecanoyl (DO–) chain.
Analogues of DODEG4 and DODesDEG4 with acetyl groups
were synthesised using analogous routes to those described
above. The 4-EG bromide 5 was reacted with acetic anhydride
to give 10 (Scheme 2C), which was reacted with amines 4 and 6
to give AC-DODEG4 and AC-DOesDEG4 in 30% and 55% yield,
respectively. Compound OC-DODEG4, with an intermediate
terminal octanoyl chain length, was prepared similarly from 5
and octanoyl chloride to give bromide 11, which was then
reacted with 4 to give the lipid in 60% yield. Dodecanoyl chlor-
ide was also used to make bromide 12, which was reacted with
4 and 6 to give DO-DODEG4 and DO-DOesDEG4 (Scheme 2C
and Table 1).
Lipid : Peptide : DNA transfections
Transfections were performed in rat neuroblastoma B104 cells,
using LPDs prepared from vesicles containing the lipids, in
the presence of a 1 : 1 molar ratio of DOPE (or 1,2-dioleoyl-sn-
glycero-3-phosphocholine (DOPC) in the case of DO-DODEG4
and DO-DOesDEG4 since it was impossible to formulate these
lipids into vesicles in the presence of DOPE) and peptide A.
The cyclic sequence -CRGDC-LG of peptide A was chosen
because it binds to αv integrin receptors and we have pre-
viously demonstrated that LPDs formulated using peptide A
mediate recognition and cell-specific uptake in neuroblastoma
cells in vitro and in vivo.19,20 Control LPD formulations were
also prepared using a scrambled sequence
K16RVRRGA-CGRDC-LG (sc) which should not be recognised
by the αv integrin receptors.
The LPDs were prepared either in Opti-MEM or in water
and diluted by 1 in 4 with Opti-MEM, and the results are
shown in Fig. 3. The preparation of LPDs in Opti-MEM was to
allow a comparison with other researchers who have used this
protocol. All LPDs tested were formulated at
lipid : peptide : DNA (L : P : D) charge ratios of 0.25 : 6.5 : 1
(equivalent to a weight ratio in the range 0.7–1 : 4 : 1, the exact
weight ratio depending upon the particular cationic lipid
used) since this was the charge ratio found to produce the
highest transfection results during a preliminary screen using
B104 cells (Fig. S2, ESI†). The preliminary screen (B104 cells)
with LPDs were made from cationic vesicles containing DOPE
and either DODEG4, TC-DODEG4, DOSEG3 and TC-DOSEG3
together with peptide A at final L : P : D weight ratios of
0.5 : 4 : 1, 1 : 4 : 1, 2 : 4 : 1 and 3 : 4 : 1. The level of transfection
achieved using LPDs with the higher lipid weight ratio of
3 : 4 : 1 was ∼20% of that obtained for the lower lipid ratios of
1 : 4 : 1 or 0.5 : 4 : 1. LPDs prepared using these lower weight
ratios produced similarly high levels of transfection.
Transfections were repeated on more than one occasion and
while diﬀering absolute levels of transfection were obtained on
diﬀerent occasions the order of transfection eﬃciencies were
consistent between experiments.
As can be seen in Fig. 3, regardless of whether the LPDs
were initially prepared in Opti-MEM or water, the LPDs made
at a L : P : D charge ratio of 0.25 : 6.5 : 1 using the TC lipids of
Group 1 exhibited superior transfection abilities to those pre-
pared using DC lipids. Increases in transfection ranged from a
5-fold in the case of LPDs containing DOSEG3 and DODEG4 to
a 200 and 300-fold increase in the case of LPDs prepared using
DOesSEG3 and DOesDEG4, respectively, suggesting that the
presence of a short ethylene glycol chain had a detrimental
eﬀect on transfection in vitro. Although the acetyl and, to a
lesser extent, the methoxy-capped analogues exhibited a slight
improvement in transfection eﬃciency, this increase was not
as high as that obtained when using the corresponding oleoyl
containing TC analogues. In contrast the OC- and DO-deriva-
tives of DODEG4 (Group 2 lipids), gave comparable transfec-
tion levels to the LPDs prepared using TC-lipids. Note that the
DO-derivative of DOesDEG4 exhibited a low level of transfec-
tion, less than that achieved with AC-DOesDEG4. LPDs pre-
pared using DOTMA and DOTAP exhibited similar transfection
eﬃciencies to the TC- and OC-lipids, suggesting that the pres-
ence of a third acyl chain negates the detrimental eﬀect of the
short ethylene glycol chain on in vitro transfection.
For the purposes of comparison, polyplexes (PD) of peptide
A: DNA (prepared at a charge ratio of 6.5 : 1) and lipoplexes of
Lipofectamine and L2K (prepared at lipid : DNA weight ratios
of 5 : 1 and 4 : 1, respectively) were also examined for their
transfection ability (Fig. 3). The polyplex demonstrated an
extremely poor transfection eﬃciency, a result in line with pre-
vious studies15 while the use of complexes prepared using
Fig. 3 In vitro transfection eﬃciency (expressed as RLU mg−1 protein)
obtained in B104 cells after exposure to LPDs prepared at a
lipid : peptide : DNA charge ratio of 0.25 : 6.5 : 1 in either Opti-MEM (grey
bars) or in 25% v/v water then diluted with Opti-MEM (black bars).
Cationic lipid used to prepare the LPDs shown on the abscissa were for-
mulated with DOPE or *DOPC. PDs prepared at a peptide : DNA charge
ratio of 6.5 : 1, and LDs of Lipofectamine and L2K prepared at weight
ratios of 5 : 1 and 4 : 1, respectively. Peptide and DNA used in all cases
were peptide A and gWiz plasmid DNA (pDNA), respectively. Data is the
mean of three measurements ± standard deviation.
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Lipofectamine and L2K generally resulted in similar or lower
transfection levels and higher toxicities than those achieved
with LPDs prepared using the TC lipids, some DC lipids,
DOTMA or DOTAP. Transfection experiments were performed
on at least three separate occasions and the trends observed
(Fig. 3) were reproducible. Scrambling of peptide A resulted in
a 70–75% decrease in transfection confirming selective target-
ing of the B104 cells by peptide A. Complexes prepared in the
absence of a targeting peptide i.e. TC lipid : DNA (LDs) have
recently been published in a separate study.25 The LDs pre-
pared from TC lipids also showed superior transfection
eﬃciencies compared to their DC equivalents, however the
absolute transfection eﬃciency of the LDs was lower by around
an order of magnitude.25
LPDs prepared fully in Opti-MEM generally showed better
transfection eﬃciency than those prepared in 25% v/v water,
followed by dilution with Opti-MEM before applying onto the
cells. The reasons are not currently understood but could be
due to diﬀerences in the size of the complexes when prepared
in Opti-MEM as opposed to water (particle size of the com-
plexes prepared fully in Opti-MEM were larger than those pre-
pared in water), and/or the looser association of DNA with the
peptide and the lipid when formulated in Opti-MEM due to
the presence of electrolyte that partially neutralises the cat-
ionic charge on the peptides and lipid. However, similar
trends in transfection were observed regardless of the Opti-
MEM or water content, the only exception being DO-DODEG4
which exhibited a far lower transfection eﬃciency when pre-
pared in water rather than Opti-MEM.
An assay to determine the percentage protein in each well
compared to blank (untreated) cells was simultaneously per-
formed with every transfection experiment to give an indi-
cation of any toxicity caused by the various formulations
(Fig. S3, ESI†). Significantly, the cells exposed to the LPD for-
mulations generally exhibited greater than 80% protein
content, suggesting that the formulations caused little or no
toxicity. The only cells exhibiting a lower protein content of
∼60% were those exposed to LPDs prepared using the
TC-DOesSEG3 and then only when the LPDs were formulated
in water and diluted with Opti-MEM, i.e. not fully prepared in
Opti-MEM. Notably, both Lipofectamine and L2K exhibited
considerable toxicity towards the cells as evidenced by the
∼65–70% and 35–55% protein contents obtained when in the
cells exposed to LDs prepared either fully in Opti-MEM or in
water and diluted with Opti-MEM, respectively.
In addition, some transfection studies were performed to
investigate the influence of the neutral co-lipid lyso-PE on the
eﬀectiveness of DNA delivery. In these studies, lyso-PE was
used in the place of DOPE during the preparation of LPDs.
Previous reports have suggested that replacing DOPE with lyso-
PE in cationic liposome formulations reduces the eﬀective
volume of the lipid hydrophobe, thus lowering the curvature
stress of the liposomes which in turn, results in liposome for-
mulations that cannot eﬀectively induce cell–cell fusion.26 It
was possible therefore that the presence of lyso-PE in an LPD
formulation might lead to a reduction in transfection
eﬃciency. A screen of LPDs prepared using an equimolar
amount of TC-lipid and lyso-PE in place of DOPE to mimic the
fact that lyso-PE would be formed during the transacylation
process (Fig. S4, ESI†) showed that LPDs containing both TC-
lipid and lyso-PE tended to be similar to or slightly more
eﬀective at transfecting B104 cells, with no significant detri-
mental eﬀect on toxicity as assessed by determination of the
percentage protein in each well. This observation supports the
hypothesis that it is the TC-lipid and not the lyso-PE formed
that is the beneficial transfection agent in these studies.
A series of biophysical experiments were then performed to
understand the reasons for the enhancement in transfection
observed with the Group 1 and Group 2 TC lipids. Of particular
interest was whether the use of a TC lipid resulted in a
diﬀerent LPD structure than has been previously observed
for LPDs formed by DC lipids,5 where biophysical studies
showed that the lipopolyplexes consisted of a core of DNA
complexed with peptide surrounded by a bilayer of lipid.
Studies using LDs prepared from TC lipids showed a major
structural re-organisation of the lipid bilayer, suggesting
that the third chain may fold over and create inter-digitated
structures.25 It is not known, however how the trichain lipids
behave in ternary systems in the presence of a targeting
peptide.
Size and zeta potential
The apparent hydrodynamic size (assuming spherical par-
ticles) and zeta potential of the cationic lipids formulated in
water were determined, either as vesicles with DOPE at
1 : 1 molar ratio or as LPDs at lipid : peptide A : gWIZ plasmid
(pDNA) charge ratios of 0.25 : 6.5 : 1, measured at cationic lipid
concentrations of 5 μg mL−1 and 1 μg mL−1, respectively
(Fig. 4). With the exception of the vesicles formed using the
Group 2 lipid, DO-DOesDEG4, which were ∼110 nm, all vesi-
cles prepared using Group 1 and Group 2 lipids exhibited sizes
in the range 45–80 nm, and polydispersities of between 0.1–0.3
(Fig. 4a and b). The size of the DC-containing vesicles, includ-
ing those prepared using methyl capped lipids, tended to be at
the lower end of the size range suggested that these vesicles
are predominately unilamellar in nature, although the pres-
ence of a small population of multilamellar structures cannot
be dismissed.
By way of comparison, vesicles prepared using the longer
acyl chain TC lipids (i.e. a third acyl chain of C8 and above)
tended to be slightly larger than their DC counterparts. The
observation that the longer acyl chain TC lipids, when in com-
bination with DOPE, formed vesicles was unexpected. Indeed,
because of the relatively large hydrophobic regions of both the
TC lipids containing an acyl chain of C8 and above and DOPE,
mixtures of such lipids with DOPE had been expected to
promote the formation of reverse structures such as reverse
hexagonal phases.
All vesicles (prepared from Group 1 and Group 2 lipids)
exhibited a zeta potential of at least ∼30 mV (DOSEG3-contain-
ing vesicles), although the typical value was in the range
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40–50 mV, indicating that the vesicles should exhibit a high
stability (Fig. 4a and b).
The apparent hydrodynamic sizes recorded for the LPDs
were similar, although slightly larger than those obtained for
the vesicles at between 55–115 nm, with most being less than
80 nm, with polydispersities in the range 0.1–0.4. Significantly,
the zeta potentials measured for the LPDs were still positive,
albeit lower than the vesicles at 15–45 mV, suggesting that the
LPDs may be less stable. Interestingly, no correlation between
the size and zeta potential of the LPDs and the structure of the
cationic lipids used to prepare the complexes was evident.
Transmission electron microscopy
Transmission electron microscopy (TEM) in combination with
negative staining using a 4% w/v solution of uranyl acetate was
used to examine the structure of the vesicles (co-formulated at
a 1 : 1 molar ratio with DOPE) and LPDs (prepared from cat-
ionic vesicles, peptide A and gWIZ plasmid pDNA at a
0.25 : 6.5 : 1 charge ratio) made using a selection of Group 1
DC and TC lipids, namely DODEG4, TC-DODEG4, DOSEG3
and TC-DOSEG3 (Fig. 5). Significantly, although some polydis-
persity in size was apparent, the aggregates observed were pre-
dominately spherical in nature, irrespective of whether the cat-
ionic lipid used was a DC or TC, supporting the presence of
vesicular structures (Fig. 5a–d). Although vesicles are not visu-
alised well using TEM, since the sample is dehydrated upon
staining, TEM was performed in order to rule out the for-
mation of other aggregate types, since to our knowledge this is
the first time that LPDs have been prepared from lipids con-
taining three long (C18:1) acyl chains.
In contrast to the spherical nature of the vesicles, the LPD
formulations (Fig. 5e–h) consisted of a mixture of spherical
and rod-shaped particles, with no apparent visible internal
structure: an observation in agreement with LPD formulations
reported previously.15,27 This observation is probably a conse-
quence of the fact that the ratio of lipid : peptide : DNA was not
fully optimised in the present study. Furthermore, there were
some observable diﬀerences between the LPDs prepared using
the DC and TC lipids in that the LPDs formulated from the DC
lipids were relatively monodisperse with individual particles of
between 50–100 nm in diameter, while the LPDs prepared
using the TC lipids, although similar in shape were more poly-
disperse and displayed some particle aggregation (Fig. 5f
and h). It is not known at present whether these aggregates are
due to drying and/or surface eﬀects, although it should be
noted that the size of the LPDs measured by dynamic light
scattering suggested that when in solution the LPDs are not
(significantly) aggregated. Furthermore, the LPDs were
prepared freshly for the TEM study.
Small angle neutron scattering
Table 2 shows the structural parameters obtained through
model fitting of small angle neutron scattering (SANS) data
obtained for cationic vesicles containing 50 mol% DOPE (at a
cationic lipid concentration of 1 mg mL−1) and LPDs prepared
at a L : P : D charge ratio of 0.25 : 6.5 : 1 (containing 0.175
mg mL−1 of K16 peptide and 0.0625 mg mL−1 of ctDNA) as
single, flat sheets (or bilayers) with or without the presence of
stacks thereof. The data for the corresponding vesicles and
LPDs formed from DOTMA and DOTAP are also included in
Table 2. A representative selection of the SANS profiles
recorded for the cationic lipid : DOPE vesicles (those made
from DOesDEG4, TC-DOesDEG4 and Me-DOesDEG4) together
with the LPDs (prepared using ctDNA and K16 at L : P : D
charge ratios of 0.25 : 6.5 : 1) are shown in Fig. 6.
Regardless of the presence and length of a third chain, all
the cationic vesicles examined in the present study were well
modelled assuming the presence of single, flat sheets (i.e. uni-
lamellar vesicles) and, where necessary, with the addition of
stacks (i.e. multilamellar vesicles). The size of all the cationic
vesicles in the present study are too large to be analysed by the
SANS instrument used here as spherical structures. Indeed,
the assumption of flat sheets is in line with the apparent
hydrodynamic size of the vesicles made in earlier studies on
related, DC cationic lipid-containing systems.13 As with the
vesicles, it was possible to analyse the LPDs formed by all the
Group 1 and Group 2 DC and TC lipids assuming the presence
of sheets or bilayers of lipid. Significantly, in the absence of
Fig. 4 The apparent hydrodynamic size (grey bars) and zeta potential
(black squares) of (a) cationic lipid vesicles prepared using at 1 : 1 molar
ratio of DOPE or *DOPC and (b) LPD complexes prepared using cationic
lipid vesicles, peptide A and pDNA at L : P : D charge ratios of
0.25 : 6.5 : 1. Measurements were performed at a cationic lipid concen-
tration of 5 μg mL−1 for vesicles and a DNA concentration of 1 μg mL−1
for LPDs. Data is the mean of three independent measurements ± stan-
dard deviation.
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any data suggesting the presence of non-vesicular structures, it
was reasonable to assume that the LPDs prepared using the
TC lipids were, as with the LPDs prepared using DC lipids,
composed of a lipid bilayer (or bilayers). This observation is
supported by the results of the transmission electron
microscopy study.
The SANS profiles of the vesicles and LPDs were measured
on more than one occasion. This was important as vesicles
prepared from the TC cationic lipids were expected to be less
stable than their DC counterparts. Indeed, preliminary studies
suggested that the amount of multilamellar structure present
in the vesicles containing the DC lipids was consistently very
low, while the amount in vesicular preparations containing a
TC lipid tended to be higher depending on the age of the vesi-
cles, particularly if the vesicles were over 1 month old.
Significantly, however, the thickness of bilayer present in the
TC vesicles did not change over the corresponding time
period. When the LPDs were prepared from freshly made vesi-
cles there was little evidence of the presence of any multilamel-
lar structures, regardless of the nature of the lipid (DC or TC)
used. However, if the LPDs were prepared from vesicles in
which a significant amount of multilamellar structure was
present, the LPDs exhibited a greater content of multilamellar
structure. The data shown in Table 2 was acquired using
freshly prepared vesicles and LPDs so the level of multilamel-
lar content was very low.
Inspection of the values of the bilayer thickness, L,
obtained for vesicles prepared from Group 1 and Group 2 DC
and TC lipids in the presence of DOPE (Table 2) showed,
perhaps somewhat surprisingly, that there was no change in
the bilayer thickness of the lipids as a function of bond type
(ester or ether), length of the n-EG linker and the absence/pres-
ence or length of a third chain. Furthermore, regardless of
whether the cationic lipid was a DC or TC, the thickness of the
Fig. 5 Transmission electron micrographs of lipid vesicles composed of a molar ratio of DOPE and cationic lipid (a) DODEG4, (b) TC-DODEG4, (c)
DOSEG3 and (d) TC-DOSEG3; and LPDs formulated with peptide A and pDNA at charge ratios of 0.25 : 6.5 : 1 using (e) DODEG4, (f ) TC-DODEG4, (g)
DOSEG3 and (h) TC-DOSEG3; and (i) PD prepared from peptide A : pDNA complexes at 6.5 : 1 charge ratio. All samples were stained with a 4% w/v
uranyl acetate solution.
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water layer between the bilayers, when present, varied between
1.7 and 1.9 nm, suggesting a water layer between each bilayer
of ∼2 nm, in line with previous results for other DC cationic
vesicles.13
Interestingly the thickness of the bilayer was much greater
when the cationic lipids were part of an LPD, with the thick-
ness of the bilayers containing the DC lipids typically increas-
ing by between ∼2.2 and 3.2 nm, while the increase in the
bilayer containing the TC lipids was even larger in the range
2.8–5.3 nm. The methoxy capped lipids behaved more like
the DC lipids exhibiting an increase in bilayer thickness of
2.6–3.6 nm. These results suggest a significant re-arrangement
of the lipids in the presence of DNA, to accommodate the
interaction of the cation with the negative charges on DNA,
with the re-arrangement being greatest for the TC lipids. In
contrast, DOTMA and DOPE and indeed previous SANS studies
on vesicles and their corresponding LPDs prepared from cat-
ionic lipids without a short ethylene glycol chain did not
exhibit any diﬀerence in bilayer thickness between the vesicles
and LPDs.15
A limited SANS study was performed using LPDs prepared
at a L : P : D charge ratio of 0.25 : 6.5 : 1 but containing
0.15 mg mL−1 of ctDNA and either 0.42 mg mL−1 of K16
peptide or 0.6 mg mL−1 of peptide A to see the eﬀect of con-
centration on the structure of the LPDs (Fig. S5, ESI† shows
the vesicles and LPDs prepared from TC-DODEG). The thick-
ness of the bilayer and lamellar d-spacing present in the LPDs
prepared using the higher level of peptides K16 and A were L =
9.3 ± 0.1 and D = 13.4 ± 0.1 (K16) and L = 8.8 ± 0.2 and D =
12.5 ± 0.1 (peptide A). These compared favourably to values of
L = 9.5 ± 0.3 and D = 11.8 ± 0.1 nm when the LPDs were pre-
pared at a ctDNA concentration of 0.0625 mg mL−1 and con-
tained 0.175 mg mL−1 of K16 peptide, suggesting that the
concentration of LPDs had no eﬀect under the present experi-
mental conditions. Similar results were obtained for LPDs pre-
pared using all of the cationic lipids tested.
Circular dichroism
Circular dichroism (CD) spectra of LPDs prepared using repre-
sentative Group 1 DC and TC lipids, DOSEG3 and TC-DOSEG3
respectively, either peptide A or K16 peptide and calf thymus
DNA (ctDNA) at a 0.25 : 6.5 : 1 charge ratio was measured and
compared to a solution containing the same concentration of
ctDNA (0.05 mg mL−1) (Fig. 7). All samples were prepared in
D2O in order to increase the optical transparency of the solu-
tion at low wavelengths. Dynamic light scattering measure-
ments of vesicles and LPDs made in D2O showed no diﬀerence
in size suggesting that the replacement of H2O with D2O does
not significantly alter the structure of the complexes. The CD
spectrum obtained for ctDNA in solution (Fig. 7) showed that
ctDNA adopts a B type conformation (namely a positive peak
at ∼275 nm and a negative region between 260–230 nm)
typical of DNA. A similar CD spectrum was obtained for pDNA
(data not shown).
The CD spectra obtained for the DC and TC LPDs prepared
using either peptide exhibited a red shift in the CD spectrum
above ∼240 nm. Since there is no absorbance either from the
peptide or the lipid above 240 nm (Fig. S6, ESI† shows the
spectra of free peptide and lipid at the same concentration as
used in the LPDs) this suggests that the conformation of
ctDNA is altered when in the form of an LPD, most likely
adopting a more condensed structure. Similar results have
been obtained in previous studies using LPD formulations.27
Interestingly, while no diﬀerence in the extent of the red shift
was observed with the type of lipid used, a greater red shift
was seen in the LPDs containing peptide A. These results
suggest that the ctDNA in the LPD complex is predominantly
condensed by the peptide with relatively little contribution
from the lipid present. This result also agrees with the LPD
structure model described previously5 wherein the LPDs were
proposed as having a core composed of predominately
DNA : peptide surrounded by a bilayer of cationic lipid.
Gel electrophoresis
Gel electrophoresis was performed on LPDs prepared using
the Group 1 and Group 2 DC and TC lipids, peptide A and
pDNA at charge ratios of 0.25 : 6.5 : 1 and the corresponding
polyplex (PD) to determine the extent of complexation of,
Table 2 Structural parameters obtained through model ﬁtting of small
angle neutron scattering data of freshly prepared cationic vesicles con-
taining 50 mol% DOPE at a cationic lipid concentration of 1 mg mL−1,
and LPDs prepared at a L : P : D charge ratio of 0.25 : 6.5 : 1 and contain-
ing K16 peptide at a DNA concentration of 0.0625 mg mL−1
Cationic lipid L (nm) D (nm)
DOTMA V 4.2 ± 0.1 V 6.2 ± 0.1
LPD 4.2 ± 0.3 LPD 6.5 ± 0.1
DODEG4 V 4.1 ± 0.1 ND
LPD 6.3 ± 0.2 ND
TC-DODEG4 V 4.2 ± 0.1 V 5.9 ± 0.1a
LPD 9.5 ± 0.3 LPD 11.8 ± 0.1
DOSEG3 V 4.1 ± 0.1 ND
LPD 6.4 ± 0.2 ND
TC-DOSEG3 V 4.0 ± 0.1 V 5.9 ± 0.1a
LPD 6.8 ± 0.2 LPD 11.6 ± 0.1
DOTAP V 4.2 ± 0.1 V 6.2 ± 0.1
LPD 4.2 ± 0.3 LPD 6.5 ± 0.1
DOesDEG4 V 3.9 ± 0.1 ND
LPD 6.9 ± 0.3 ND
TC-DOesDEG4 V 4.1 ± 0.1 V 5.8 ± 0.3
LPD 7.8 ± 0.4 ND
Me-DOesDEG4 V 4.0 ± 0.1 ND
LPD 7.6 ± 0.5 ND
DOesSEG3 V 4.1 ± 0.1 V 6.0 ± 0.1
LPD 7.3 ± 0.3 ND
TC-DOesDEG3 V 4.1 ± 0.1 ND
LPD 9.1 ± 0.4 LPD 13.0 ± 0.1
Me-DOesDEG3 V 4.0 ± 0.1 ND
LPD 6.6 ± 0.3 ND
AC-DODEG4 V 3.9 ± 0.1 ND
OC-DODEG4 V 3.8 ± 0.1 V 5.9 ± 0.1
DO-DODEG4 V 3.9 ± 0.1 ND
L is the vesicle bilayer thickness (in nm), D the lamellar d-spacing (in
nm). Standard errors on the fitted parameters are shown. V is data
obtained for vesicles and LPD is data obtained for LPDs. ND = no
stacks (multilamellar structure) determined. aHere M (the number of
stacks in a multilayer structure) = 5.
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enzyme protection aﬀorded to, and release of DNA (Fig. 8,
Lanes A, B and C, respectively). The extent of protection of
pDNA in the LPDs against DNAse I, was measured using two
amounts of DNAse I, namely single strength (1 IU per µg of
pDNA) and double strength (2 IU per µg of pDNA) DNAse I
(Fig. 8 Lane B). Double strength DNAse I was used to help elu-
cidate trends.
It was evident that all the LPDs as well as the PD were able
to condense pDNA completely as no migration of pDNA down
any Lane A was observed (Fig. 8). Significant diﬀerences
between the protection from DNAse I aﬀorded by the various
lipids was, however, observed when the complexes were treated
with DNAse I (Fig. 8, Lanes B). Generally, LPDs formulated
using the Group 1 TC lipids, DOTMA or DOTAP protected
pDNA to a greater extent than LPDs formulated with the DC
lipids and, to a lesser extent, the Group 2 lipids. In the case of
the DC lipids, a greater amount of low molar weight pDNA
fragments were particularly evident. These diﬀerences were
particularly noticeable when double strength DNAse I was
used (Fig. 8b). Taken together these results suggest that the
pDNA is well complexed by the peptide and that the lipids add
little benefit in this respect. The diﬀerent lipids however
protect the pDNA to various extents supporting the hypothesis
that the lipid forms a barrier between the lipid and DNA. This
suggestion is further supported by the fact that no uncomplexed
DNA was observed.
Fig. 6 Small angle neutron scattering data (dots) recorded at 298 K and the best ﬁt to the data (solid line) obtained using the mixed sheet and stack
model for freshly prepared vesicles prepared from DOPE and 1 : 1 molar ratio of cationic lipid: (a) the dichain lipid, DOesDEG4, (c) the corresponding
trichain lipid TC-DOesDEG4, and (e) their methoxy capped dichain counterpart Me-DOesDEG4, at a cationic lipid concentration of 1 mg mL−1 and
LPDs prepared from these vesicles containing (b) DOesDEG4, (d) TC-DOesDEG4, and (f ) Me-DOesDEG3, peptide K16 at a ctDNA concentration of
0.0625 mg mL−1 and a L : P : D charge ratio of 0.5 : 6 : 1.
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All complexes were able to release pDNA on the addition of
excess pAsp (Lanes C), although the extent of release obtained
varied with the nature of the lipid present. LPDs prepared
using Group 1 TC lipids appeared to release more pDNA due
to the presence of brighter pDNA bands and a lower residual
fluorescence remaining in the wells. pDNA release from the
LPDs prepared using the Group 2 TC lipids was intermediate
with relatively low levels of fluorescence remaining in the
wells. In an attempt to quantify the protection and release of
pDNA from the complexes formed using the Group 1 lipids as
well as those formed using DOTMA or DOTAP, the intensities
of the DNA bands in Lane B were analysed and compared
either to the amount of pDNA in their corresponding Lane C
(i.e. the pDNA release in the absence of DNAse I) or the corre-
sponding (untreated) pDNA control band using the data
obtained in Fig. 8b (first sample on every row). The results of
this intensity analysis are shown in Table 3. With the exception
of TC-DOesDEG4, the complexes prepared with the Group 1
TC lipids, DOTMA and DOTAP exhibited much higher DNA
band intensity (52% and higher) compared to their DC equiva-
lents (28% and lower), suggesting that more DNA was pre-
served. This was also mirrored by observing brighter low mole-
cular weight degradation bands for LPDs containing DC lipids
compared to Group 1 TC lipids, DOTMA or DOTAP, providing
further evidence that the DNA was digested to lower molecular
weight fragments to a greater extent. These observations
suggest that the bilayer formed by the TC lipids provides a
more eﬀective barrier to the degradation of DNA.
Since transfection eﬃciency was highest in LPDs prepared
using DOTMA, DOTAP or the Group 1 and Group 2 TC lipids
as opposed to their DC counterparts, and a similar trend was
observed in the pDNA protection capacity, it is possible that
the ability of the LPD complex to protect the pDNA and release
it from the LPD particle plays a major role in enhancing its
transfection eﬃciency. A similar relationship between transfec-
tion and the extent of protection and subsequent release of
the DNA payload a complex carried has been observed in our
previous studies15 as well as those reported by others.28–30
Fig. 7 CD spectra in (x-axis nm) of ctDNA and LPDs prepared using
DOSEG3 or TC-DOSEG3 in combination with either peptide A (green
and pale blue) or K16 (black and purple) at charge ratios of 0.25 : 6.5 : 1.
Measurements were performed using a 0.5 cm path length at a ﬁnal
DNA concentration of 0.05 mg mL−1.
Fig. 8 Gel condensation, protection and release assay of LPDs or PDs
prepared at 0.25 : 6.5 : 1 or 6.5 : 1 charge ratios, respectively with peptide
A, and gWIZ plasmid DNA (pDNA) at a concentration of 0.25 μg per
10 μL per well. LPDs were prepared using the DC and TC lipids and
treated in either one of three ways: Lane A = untreated LPDs (showing
DNA condensation); Lane B = LPDs treated with DNAse and pAsp
(showing pDNA protection against enzymatic degradation); Lane C =
LPDs treated with pAsp only (showing eﬃciency of DNA release from
complex). Free (untreated) pDNA and pDNA treated with DNAse I were
used as controls in each row. (a) Single strength (0.25 IU) DNAse I was
used per well and (b) double strength (0.5 IU) DNAse I was used.
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Conclusions
The identification of a novel TC lipid, formed from the helper
lipid DOPE and a cationic lipid possessing a terminal hydroxyl
group, led us to design and synthesise several trichain lipids
and the corresponding DC cytofectins. The transfection
eﬃcacies (in Opti-MEM and Opti-MEM/water) of the TC cyto-
fectins in LPD ternary vectors was significantly enhanced com-
pared to the DC analogues and therefore biophysical studies
were performed to enhance understanding of the behaviour of
lipids with three alkyl chains attached. In general, the size of
the TC lipid vesicles and LPD nanoparticles were slightly
larger than the corresponding DC-containing systems. TEM
revealed that the TC lipids formed spherical vesicles, whereas
for LPDs both spherical and rod-shaped particles were formed,
with monodisperse particles for the DCs and more polydisper-
sity with the TCs. SANS studies indicated that for vesicles with
DC and TC lipids, multilamellar structures were present: when
DC lipids were used this was low, rising to 25–50% for TC lipids.
For LPD formulations, however, there was no evidence for the
formation of multilamellar structures, only unilamellar struc-
tures of very large layer thickness, suggesting a re-arrangement
of the lipids in the presence of DNA to accommodate the inter-
action between the TCs and the negatively charged DNA. This
is the first time a re-arrangement of the lipid bilayer, on for-
mation of lipopolyplexes, has been reported. CD spectra of the
LPDs indicated that the peptide interacted with DNA preferen-
tially to the lipid, which suggests that the structure of the LPD
consists of a DNA-peptide core surrounded by a lipid bilayer as
previously shown for other DC lipids.15 Finally gel electrophor-
esis studies revealed that the TC lipids in LPD formulations
had enhanced pDNA protection properties, compared to the
corresponding DC analogues. Thus, the major enhancement
in transfection performance of the TC lipids is probably due to
their ability to protect and release DNA. At a molecular level
this may be achieved by folding back of the third hydrophobic
chain into the bilayer or partial inter-digitation of the third
alkyl chain into the other bilayer component. In summary, a
new design concept for use in eﬀective gene delivery lipids has
been identified. Further studies are now underway to probe
this eﬀect.
Experimental
Detailed experimental procedures, characterisation data, and
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